MALAT1 and exocrine pancreatic carcinoma: We therefore investigated the impact of candidate drugs gemcitabine, a commonly used anti-cancer agent against pancreatic carcinoma in clinic, on the cell proliferation, and calculated the 50% inhibitory drug concentration (IC50) following MALAT-1 knockdown.